Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Mayo Clinic · Mayo Clinic in Arizona · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,490
total citations
- FWCI
- 101.80
- Percentile
- 100%
- References
- 42
Citations per year
Authors
26- EDEugene D. KwonCorresponding
Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic in Florida
- CGCharles G. Drake
Sidney Kimmel Comprehensive Cancer Center
- HIH. I. Scher
Memorial Sloan Kettering Cancer Center, Cornell University
- KFKarim Fizazi
Université Paris-Sud, Institut Gustave Roussy
- ABAlberto Bossi
Institut Gustave Roussy
Topics & keywords
Topics
Keywords
- Docetaxel
- Medicine
- Prostate cancer
- Oncology
- Internal medicine
- Placebo
- Chemotherapy
- Radiation therapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.